Opinion|Videos|July 2, 2024
Examining 3-Year Update Data from the CASPIAN Trial
A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.
Advertisement
Episodes in this series
- Please review the 3-year overall survival update from the CASPIAN trial, assessing durvalumab ± tremelimumab plus platinum-etoposide in the first-line treatment of ES-SCLC, and discuss the impact of these findings on the treatment landscape. (
Paz-Ares L, et al. ESMO Open. 2022: 7(2):100408 )- Please comment on how clinical outcomes from this trial have influenced the treatment algorithm for ES-SCLC and the importance of the long-term follow-up data.
- From a clinical perspective, how impactful to you and to your patients with ES-SCLC is the survival rate, which tripled from 6% to 18% at 3 years in the CASPIAN clinical trial?
- With the updated CASPIAN trial outcomes and the endpoints from ADRIATIC, can we now extrapolate the survival benefits with immunotherapy, which apply to all stages of SCLC?
- In the exploratory analysis of the CASPIAN Phase III clinical trial, a similar prevalence of neuroendocrine and non-neuroendocrine subtypes was detected in a subgroup of 104 patients with RNA sequencing data. However, Inflamed or YAP1 subtypes in the durvalumab + etoposide treatment arm experienced the longest overall survival.
- What characteristics of these SCLC subtypes suggest that they may be betterprimed to respond to immunotherapy, and what are some future clinical implications of this finding?
Advertisement
Related to this article
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5